血必净治疗布鲁氏菌病的临床疗效观察

Observation on clinical efficacy of Xuebijing in treating brucellosis

目的 探究血必净治疗布鲁氏菌病的临床疗效。方法 100例布鲁氏菌病患者,根据住院号尾数随机分为治疗组和对照组,各50例。对照组采用西医治疗,治疗组在对照组治疗基础上加用血必净治疗。对比两组治疗效果、不良反应发生情况、复发率、C反应蛋白下降时间及治疗前后纤维蛋白原、D-二聚体水平。结果 治疗组治疗总有效率98.00%显著高于对照组的78.00%(P<0.05)。治疗组不良反应发生率2.00%低于对照组的18.00%(P<0.05)。2个月后随访,治疗组复发率2.00%(1/50)低于对照组的18.00%(9/50)(P<0.05)。治疗组C反应蛋白下降时间(7.54±2.94)d短于对照组的(7.54±2.94)d(P<0.05)。治疗后,治疗组纤维蛋白原、D-二聚体水平分别为(3.01±0.41)g/L、(0.81±0.41)mg/L,均低于对照组的(3.89±0.55)g/L、(1.76±0.52)mg/L(P<0.05)。结论 血必净治疗布鲁氏菌病的临床疗效显著,能够有效控制病情并减少不良反应发生,促使其尽快恢复,建议临床推广采纳。

Objective To explore the clinical efficacy of Xuebijing in treating brucellosis.Methods 100 patients with brucellosis were randomly divided into a treatment group and a control group according to hospitalization number,with 50 cases in each group.The control group was treated with Western medicine,and the treatment group was treated with Xuebijing on the basis of the control group.The treatment effect,occurrence of adverse reactions,recurrence rate,time to decrease of C-reactive protein,fibrinogen and D-dimer levels before and after treatment were compared between the two groups.Results The total effective rate of the treatment group was 98.00%,which was significantly higher than the control group's 78.00%(P<0.05).The incidence of adverse reactions in the treatment group was 2.00%,which was lower than the control group's 18.00%(P<0.05).After 2 months follow-up,the recurrence rate in the treatment group was 2.00%(1/50),which was lower than the control group's 18.00%(9/50)(P<0.05).The time to decrease of C-reactive protein was(7.54±2.94)d in the treatment group,which was shorter than(7.54±2.94)d in the control group(P<0.05).After treatment,the levels of fibrinogen and D-dimer in the treatment group were(3.01±0.41)g/L and(0.81±0.41)mg/L,which were lower than(3.89±0.55)g/L and(1.76±0.52)mg/L in the control group(P<0.05).Conclusion Xuebijing has remarkable clinical efficacy in treating brucellosis,which can effectively control the disease and reduce the occurrence of adverse reactions,and promote its recovery as soon as possible.So it is recommended to be promoted in clinical practice.